Perfusion imaging of high-grade gliomas: a comparison between contrast harmonic and magnetic resonance imaging
| Autor: | Walter Möller-Hartmann, Markus Florian Oertel, Christof Klötzsch, Judith U. Harrer |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.diagnostic_test
Brain Neoplasms Ultrasonography Doppler Transcranial business.industry Area under the curve Perfusion scanning Magnetic resonance imaging Blood volume Glioma Middle Aged Image Enhancement medicine.disease Magnetic Resonance Imaging Central nervous system disease Reference Values Regional Blood Flow medicine Humans Female Nuclear medicine business Perfusion Brain neoplasm Aged |
| Zdroj: | Journal of Neurosurgery. 101:700-703 |
| ISSN: | 0022-3085 |
| DOI: | 10.3171/jns.2004.101.4.0700 |
| Popis: | ✓ Transcranial contrast harmonic (CH) imaging is emerging as a promising tool for the evaluation of brain perfusion. The authors report on two cases of histologically proven high-grade gliomas evaluated using CH imaging in comparison to perfusion magnetic resonance (pMR) imaging. In both cases, pMR imaging results demonstrated a massive decrease in signal intensity and an elevated regional cerebral blood volume (rCBV) in the tumor region; however, signal decrease was less prominent and rCBV was lower in healthy brain tissue. In one patient, the rCBV ratio of tumor/brain was 5.0 and the maximal signal decay occurred 3.1 times deeper in the tumor than in the healthy brain tissue. Results of an ultrasonography examination using CH imaging revealed similar data: the tumor/brain ratio for the area under the curve, a parameter corresponding to rCBV, was 4.1. The maximal signal intensity in the tumor was 3.3 times greater than in adjacent healthy brain. Comparable data were obtained in a second patient. Taken together, these findings indicate that CH imaging may be a valuable alternative to pMR imaging. This new, cost-effective bedside ultrasonic technique could be helpful not only as a means of noninvasive staging of gliomas but also as a follow-up imaging modality to evaluate postoperative tumor recurrence or response to antiangiogenic therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|